

AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-26 (Canceled)

27. (Previously presented) A human or humanized antibody having the binding specificity of the IK17 antibody, wherein the antibody is selected from the group consisting of: a monoclonal antibody (Mab), a fragment antibody (Fab), and a single chain fragment (scFv); wherein the antibody, fragment antibody or single chain fragment is specific for oxidation specific epitopes found on copper-induced oxidized low density lipoprotein (Cu-OxLDL) and malondialdehyde low density lipoprotein (MDA-LDL); wherein the antibody or fragment antibody or single chain fragment does not bind to native LDL; wherein the antibody or fragment antibody or single chain fragment inhibits uptake of Cu-OxLDL by macrophages; and wherein the antibody or fragment antibody or single chain fragment binds such epitopes *in vivo* at a detectably higher rate than the rate of binding to normal vasculature.

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Currently amended) ~~A human or humanized antibody~~ The antibody according to claim 27, wherein the antibody comprises a variable light chain encoded by a nucleotide sequence of SEQ ID NO:1 and a variable heavy chain encoded by a nucleotide sequence of SEQ ID NO:2.

32. (Canceled)